BMJ 341:c4444PubMed 161. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657–663PubMed 162. Nguyen DM, Schwartz J, Richardson P, El-Serag HB (2010) Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. selleck products Dig Dis Sci 55:3404–3407PubMed 163. Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip
fracture. N Engl J Med 357:1799–1809PubMed 164. Cummings SR, Schwartz AV, Black DM (2007) Alendronate and atrial fibrillation. N Engl J Med 356:1895–1896PubMed 165. Karam R, Camm J, McClung M (2007) Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357:712–713, author reply 714-715PubMed 166. Lewiecki EM, Cooper C, Thompson E, Hartl F, Mehta D, Papapoulos SE (2010) Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 64:821–826PubMed 167. Varma R, Aronow WS, Basis Y, Singh KU55933 research buy T, Kalapatapu K, Weiss MB, Pucillo AL, Monsen CE (2008) Relation of
bone mineral density to frequency of coronary heart disease. Am J Cardiol 101:1103–1104PubMed 168. Choi SH, An JH, Lim S et al (2009) Lower bone mineral density is associated with higher coronary calcification and coronary plaque burdens by multidetector row coronary computed tomography in pre- and postmenopausal women. Clin Endocrinol (Oxf) 71:644–651 169. Eriksen EF, Lyles KW, Colon-Emeric
CS et al (2009) Antifracture efficacy and reduction of mortality in relation to Verubecestat price timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24:1308–1313PubMed 170. McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA (1987) Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 8(Suppl 1):S35–41PubMed 171. Brinkmeier T, Kugler K, Lepoittevin JP, Frosch PJ (2007) Adverse cutaneous drug reaction to alendronate. Contact Dermatitis 57:123–125PubMed 172. Krasagakis K, Kruger-Krasagakis S, Ioannidou D, Tosca A (2004) Chronic erosive and ulcerative oral lesions caused by incorrect administration of alendronate. J Am Bcl-w Acad Dermatol 50:651–652PubMed 173. Yanik B, Turkay C, Atalar H (2007) Hepatotoxicity induced by alendronate therapy. Osteoporos Int 18:829–831PubMed 174. Phillips MB (2007) Risedronate-induced hepatitis. Am J Med 120:e1–2PubMed 175. Coleman R, Cook R, Hirsh V, Major P, Lipton A (2011) Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117:11–23PubMed 176. Gnant M, Clezardin P (2012) Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev (in press) 177. Normanno N, De Luca A, Gallo M, Lamura L, Perrone F (2011) Zoledronic acid in early-stage breast cancer. Lancet Oncol 12:991PubMed 178.